Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)

Malaria Clinical Trial

— CHMI-SIKA  

Official title:

Controlled Human Malaria Infection (CHMI) to Assess Human Immunity to P. Falciparum Using Sporozoites Administered by Direct Venous Inoculation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02739763
• Other study ID #: OXTREC 2-16
• Secondary ID: KEMRI/CGMRC/CSC/
• Status: Recruiting
• Phase: Phase 1
• First received: April 13, 2016
• Last updated: May 27, 2016
• Start date: May 2016
• Est. completion date: November 2020

Study information

• Verified date: May 2016
• Source: University of Oxford
• Contact: Melissa Kapulu, DPhil
• Phone: +254709983463
• Email: MKapulu[@]kemri-wellcome.org
• Is FDA regulated: No
• Health authority: Kenya: KEMRI Scientific and Ethics Review UnitUK: Oxford Tropical Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The investigators wish to understand how resistance to malaria develops and how this affects the growth rate of malaria in individuals who have past exposure to malaria.

Description:

Malaria remains a major public health threat despite regulatory approval of a partially effective pre-erythrocytic malaria vaccine. There is an urgent need to accelerate the development of a more effective multi-stage vaccine. Controlled human malaria infection (CHMI) has been shown to be an important tool for the assessment of the efficacy of novel malaria vaccines and drugs prior to field trials. CHMI also allows for the evaluation of immunity to malaria and parasite growth rates in vivo. This is particularly useful in individuals from endemic areas with a level of exposure and immunity to malaria. Thus CHMI in individuals with prior exposure to malaria could be a valuable tool to accelerate malaria vaccine development. In this study, the investigators aim to use CHMI in semi-immune adults to provide a comprehensive prioritization of antigens associated with blood-stage immunity for vaccine development. The investigators will comprehensively characterize immunity to malaria using >100 antigens in up to 2,000 semi-immune adults, from known areas of malaria endemicity in Kenya, then select 200 individuals with a range of different immunological profiles, and conduct CHMI studies with serial quantitative polymerase chain reaction (PCR) to measure the parasite growth rate in vivo and relate this to host immunity. This will also involve analysing the relationship with functional immunity assessed by laboratory assays.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: November 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy adults aged 18 to 45 years.

• Able and willing (in the Investigator's opinion) to comply with all study requirements.

• Informed consent.

• Use of effective method of contraception for duration of study (women only). The investigators will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject's entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Exclusion Criteria:

• Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).

• Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.

• Current participation in another clinical trial or recent participation within 12 weeks of enrolment.

• Prior receipt of an investigational malaria vaccine.

• Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed).

• Use of immunoglobulins or blood products within 3 months prior to enrolment.

• Any serious medical condition reported or identified during screening that increases the risk of CHMI.

• Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.

• Women only; pregnancy, or an intention to become pregnant during the duration of the study.

• Confirmed parasite positive by PCR a day before challenge i.e. at C-1.

Exclusion Criterion on Day of Challenge:

• Acute disease, defined as moderate or severe illness with or without fever (temperature >37.5°C).

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Malaria

Intervention

Biological:
• Plasmodium falciparum sporozoite (PfSPZ)
Plasmodium falciparum sporozoites

Locations

Country	Name	City	State
Kenya	KEMRI Wellcome Trust Research Programme	Kilifi	Coast
Kenya	KEMRI Centre for Clinical Research	Nairobi

Sponsors (7)

Lead Sponsor	Collaborator
University of Oxford	KEMRI Centre for Clinical Research, KEMRI-Wellcome Trust Collaborative Research Program, Pwani University, Sanaria Inc., University of Cambridge, Wellcome Trust Sanger Institute

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Infectivity of PfSPZ (malaria infection) as determined by quantitative PCR		day 7 to day 21	Yes
Secondary	Safety profile of PfSPZ challenge via direct venous injection		day 0 to day 21	Yes
Secondary	Parasite growth rates with respect to antibody responses to over 100 falciparum antigens		day 7 to day 21	No